These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 27557118)
1. Towards precision medicine-based therapies for glioblastoma: interrogating human disease genomics and mouse phenotypes. Chen Y; Gao Z; Wang B; Xu R BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):516. PubMed ID: 27557118 [TBL] [Abstract][Full Text] [Related]
2. Drug repurposing for glioblastoma based on molecular subtypes. Chen Y; Xu R J Biomed Inform; 2016 Dec; 64():131-138. PubMed ID: 27697594 [TBL] [Abstract][Full Text] [Related]
3. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735 [TBL] [Abstract][Full Text] [Related]
4. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells. Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306 [TBL] [Abstract][Full Text] [Related]
5. Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma. Oh YT; Cho HJ; Kim J; Lee JH; Rho K; Seo YJ; Choi YS; Jung HJ; Song HS; Kong DS; Seol HJ; Lee JI; Yoon Y; Kim S; Nam DH; Joo KM PLoS One; 2014; 9(8):e103327. PubMed ID: 25084005 [TBL] [Abstract][Full Text] [Related]
6. Drug and disease signature integration identifies synergistic combinations in glioblastoma. Stathias V; Jermakowicz AM; Maloof ME; Forlin M; Walters W; Suter RK; Durante MA; Williams SL; Harbour JW; Volmar CH; Lyons NJ; Wahlestedt C; Graham RM; Ivan ME; Komotar RJ; Sarkaria JN; Subramanian A; Golub TR; Schürer SC; Ayad NG Nat Commun; 2018 Dec; 9(1):5315. PubMed ID: 30552330 [TBL] [Abstract][Full Text] [Related]
7. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma. Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558 [TBL] [Abstract][Full Text] [Related]
8. Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. Yong WH; Shabihkhani M; Telesca D; Yang S; Tso JL; Menjivar JC; Wei B; Lucey GM; Mareninov S; Chen Z; Liau LM; Lai A; Nelson SF; Cloughesy TF; Tso CL PLoS One; 2015; 10(10):e0141334. PubMed ID: 26506620 [TBL] [Abstract][Full Text] [Related]
9. Discovering gene-environment interactions in glioblastoma through a comprehensive data integration bioinformatics method. Kunkle B; Yoo C; Roy D Neurotoxicology; 2013 Mar; 35():1-14. PubMed ID: 23261424 [TBL] [Abstract][Full Text] [Related]
10. Comparison of glioblastoma (GBM) molecular classification methods. Lee E; Yong RL; Paddison P; Zhu J Semin Cancer Biol; 2018 Dec; 53():201-211. PubMed ID: 30031763 [TBL] [Abstract][Full Text] [Related]
12. Discovering key regulatory mechanisms from single-factor and multi-factor regulations in glioblastoma utilizing multi-dimensional data. Peng C; Shen Y; Ge M; Wang M; Li A Mol Biosyst; 2015 Aug; 11(8):2345-53. PubMed ID: 26091184 [TBL] [Abstract][Full Text] [Related]
13. High metallothionein predicts poor survival in glioblastoma multiforme. Mehrian-Shai R; Yalon M; Simon AJ; Eyal E; Pismenyuk T; Moshe I; Constantini S; Toren A BMC Med Genomics; 2015 Oct; 8():68. PubMed ID: 26493598 [TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling reveals Ki-67 associated proliferation signature in human glioblastoma. Jin Q; Zhang W; Qiu XG; Yan W; You G; Liu YW; Jiang T; Wang L Chin Med J (Engl); 2011 Sep; 124(17):2584-8. PubMed ID: 22040407 [TBL] [Abstract][Full Text] [Related]
15. miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal. Lulli V; Buccarelli M; Martini M; Signore M; Biffoni M; Giannetti S; Morgante L; Marziali G; Ilari R; Pagliuca A; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L Oncotarget; 2015 Nov; 6(35):37241-56. PubMed ID: 26437223 [TBL] [Abstract][Full Text] [Related]
16. Neuropathological and genomic characterization of glioblastoma-induced rat model: How similar is it to humans for targeted therapy? Sharifzad F; Yasavoli-Sharahi H; Mardpour S; Fakharian E; Nikuinejad H; Heydari Y; Mardpour S; Taghikhani A; Khellat R; Vafaei S; Kiani S; Ghavami S; Łos M; Noureddini M; Ebrahimi M; Verdi J; Hamidieh AA J Cell Physiol; 2019 Dec; 234(12):22493-22504. PubMed ID: 31120149 [TBL] [Abstract][Full Text] [Related]
17. Visualizing molecular profiles of glioblastoma with GBM-BioDP. Celiku O; Johnson S; Zhao S; Camphausen K; Shankavaram U PLoS One; 2014; 9(7):e101239. PubMed ID: 25010047 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Yang YP; Chien Y; Chiou GY; Cherng JY; Wang ML; Lo WL; Chang YL; Huang PI; Chen YW; Shih YH; Chen MT; Chiou SH Biomaterials; 2012 Feb; 33(5):1462-76. PubMed ID: 22098779 [TBL] [Abstract][Full Text] [Related]
19. SIRT5 downregulation is associated with poor prognosis in glioblastoma. Chen X; Xu Z; Zeng S; Wang X; Liu W; Qian L; Wei J; Yang X; Shen Q; Gong Z; Yan Y Cancer Biomark; 2019; 24(4):449-459. PubMed ID: 30909186 [TBL] [Abstract][Full Text] [Related]
20. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. Cohen ZR; Ramishetti S; Peshes-Yaloz N; Goldsmith M; Wohl A; Zibly Z; Peer D ACS Nano; 2015 Feb; 9(2):1581-91. PubMed ID: 25558928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]